XACT Robotics®, a privately owned company completely focuses on advancing the field of radiology by creating the world’s first and only hands-free robotic solutions that can significantly improve targeting accuracy, efficiency, and consistency in percutaneous radiology procedures. The company was founded in 2013 by Harel Gadot, a renowned entrepreneur in the MedTech robotics space, whose vision reimagined how image-guided percutaneous procedures are performed.
At XACT, the team embraces the philosophy of collaboration, tenacity, and extreme ownership. XACT’s family culture empowers and inspires as it partners, creates, and executes meaningful technologies to make a difference in the lives of patients.
The firm says, “Our company’s leadership is comprised of start-up, robotic, and disruptive technology experts with deep knowledge, vast experience and the diverse leadership skills required in the robotic market.”
The XACT ACE™ Robotic System is the world’s first and only hands-free robotic technology that combines advanced image-based procedure planning and navigation with robotic instrument insertion and non-linear steering capabilities.
Why go for XACT ACE?
The XACT ACE™ Robotic system (ACE) provides hands-free targeting with a high level of accuracy and control, to enable performing a wide variety of percutaneous procedures, including biopsies, ablations, and site-specific drug delivery. By combining image-based planning and navigation with robotic instrument insertion and non-linear steering capabilities, ACE enables users to achieve instrument tip-to-target average accuracy of < 3mm. ACE’s non-linear steering capabilities enable radiologists to access hard-to-reach locations even if the target moves during the procedure due to instrument insertion or patient movement or breathing.
By optimizing accuracy, ACE can lead to more predictable and consistent procedure times and enhanced patient outcomes. With its highly consistent and reproducible one-insertion-to-target performance, ACE minimizes the need for and incidence of instrument reinsertions, reducing procedure complexities, delays and duration. In clinical studies, ACE’s hands-free robotic skin to target time was < 8.5 minutes on average. This enables predictable procedure duration that enhances the utilization of healthcare facilities and staff.
The XACT ACE™ Robotic System has a small footprint; it is compact and portable and enables care providers to efficiently treat a board range of patient care needs across multiple areas of the body. ACE can be set up for use with patients within minutes and does not require a specialized, dedicated operating space. ACE is capable of delivering various instruments to a desired target for a wide variety of percutaneous procedures, such as ablation, biopsy and drug delivery, and is designed to be compatible with multiple imaging modalities.
For your information (News)
Lahey Hospital & Medical Center has acquired the XACT ACE™ Robotic System, for use in its leading Interventional Radiology service. ACE is the world’s first hands-free robotic technology combining advanced image-based procedure planning and navigation with robotic instrument insertion and steering capabilities enabling radiologists to deliver site-specific percutaneous solutions with accuracy, consistency, and efficiency. This benefits patients by enabling physicians to precisely target organs deep inside the body or facilitating the treatment of a disease in a location that is challenging to access.
“By investing in cutting-edge, hands-free robotic technology, we endeavor to further realize our mission of providing superior health care leading to the best possible outcome for every patient,” stated Dr. Christoph Wald, Chair of Radiology at Lahey Hospital & Medical Center. “Lahey Hospital & Medical Center chose to lead as the first hospital in the US offering robotic percutaneous procedures with this device.”
The XACT ACE Robotic system is designed to be compatible with a broad range of imaging modalities capable of delivering various medical instruments to a desired target. Its small footprint and high mobility features enable health care providers to efficiently treat a broad range of patient care needs in multiple areas of the body.
“We have actively participated in clinical research demonstrating the efficacy of XACT Robotic System leading to its approval by the FDA,” stated Dr. Sebastian Flacke, Chief of Interventional Radiology at Lahey Hospital & Medical Center. “Our input has helped to design technology that offers superior clinical outcomes and to help provide safe, cost-effective, and exceptional care to our community.”
“The XACT ACE System is poised to elevate percutaneous radiology standards by delivering enhanced clinical, technical and economic value for the healthcare providers and the patients they serve,” Harel Gadot, Executive Chairman, and President, XACT Robotics stated. “We are excited about the recent transaction with a leading institute such as Lahey Hospital and Medical Center, which allows both the medical center and its patients access to our technology and the multiple benefits it will bring them.”
Chen Levin, Chief Executive Officer
Chen is a seasoned leader in the healthcare space with vast experience in management and operational positions. Throughout her career, Chen contributed to, and played an instrumental part of, the Israeli biomed industry’s continuous growth.
Prior to leading XACT, Chen served as the Executive Director of BioJerusalem, an initiative of the Prime Minister’s Office of the government of Israel to foster the biomed industry in Jerusalem, where she established numerous ventures and collaborations. Before BioJerusalem, Chen served as the CEO of Biomagnesium Systems Ltd., an early stage medical device company. Prior to this, Chen played a key role in the establishment of BioLineRx, Israel’s first Biomed Incubator (now a TASE publicly traded company).Chen started her career in policy research, helping shape important government biomed industry support schemes. Chen is a member of the founding and steering committee of Women in the Life Sciences Organization (WLSO) in Israel.
Chen holds a BA degree in International Relations and an MBA in Finance, both from the Hebrew University of Jerusalem.